ライフサイエンスコーパス: hospital-acquired pneumonia

1 s (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia).

2 entilator-associated pneumonia or ventilated hospital-acquired pneumonia).

3 ce of ventilator-associated pneumonia or ICU-hospital-acquired pneumonia.

4 One patient died 13 days after TMVR from hospital-acquired pneumonia.

5 unity-acquired pneumonia and a rare cause of hospital-acquired pneumonia.

6 on use was associated with increased odds of hospital-acquired pneumonia.

7 an important cause of community-acquired and hospital-acquired pneumonia.

8 se was associated with 30% increased odds of hospital-acquired pneumonia.

9 ated pneumonia and 9,747 were at risk of ICU-hospital-acquired pneumonia.

10 mon pathogens associated with fatal cases of hospital-acquired pneumonia.

11 pportunistic pathogen and a leading cause of hospital-acquired pneumonia.

12 ormance for detecting community-acquired and hospital-acquired pneumonia.

13 divided into community-acquired pneumonia or hospital-acquired pneumonia.

14 an improved prognosis, particularly for ICU-hospital-acquired pneumonia.

15 compared to those of their controls; 81% had hospital-acquired pneumonia, 13% had bloodstream infecti

16 monas aeruginosa is the most common cause of hospital-acquired pneumonia and a killer of immunocompro

17 ophylaxis may, however, increase the risk of hospital-acquired pneumonia and Clostridia difficile inf

18 Pseudomonas aeruginosa causes hospital-acquired pneumonia and is associated with high

19 gionnaires' disease is an important cause of hospital-acquired pneumonia and is caused by infection w

20 Staphylococcus aureus is a major cause of hospital-acquired pneumonia and is emerging as an import

21 icular, this bacterium is a leading cause of hospital-acquired pneumonia and is responsible for infec

22 e cohort of patients, we found that both ICU-hospital-acquired pneumonia and ventilator-associated pn

23 e is an important pathogen in the context of hospital-acquired pneumonia, and a better understanding

24 Pseudomonas aeruginosa is a leading cause of hospital-acquired pneumonia, and approximately 80% of pa

25 nal and urinary tract infections, as well as hospital-acquired pneumonia, and for gram-negative infec

26 ition, standardization of antibiotherapy for hospital-acquired pneumonia, and systematic approach to

27 um Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia, as a model for investigatin

28 Hospital-acquired pneumonia caused by Staphylococcus aur

29 ase 3 studies of telavancin for treatment of hospital-acquired pneumonia, cure rates for those with b

30 Incidence of hospital-acquired pneumonia, defined via codes from the

31 The main outcome measure was hospital-acquired pneumonia, defined via International C

32 le data and unanswered questions surrounding hospital-acquired pneumonia, discuss alterations of the

33 a frequent cause of antimicrobial-resistant hospital-acquired pneumonia, especially in critically il

34 ppear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for

35 Patients who recover from hospital-acquired pneumonia exhibit a high incidence of

36 e existing definitions of pneumonia based on hospital acquired pneumonia (HAP) classifications may be

37 sorders associated with an increased risk of hospital-acquired pneumonia (HAP) and acute respiratory

38 fessionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associa

39 an audit on the adherence to guidelines for hospital-acquired pneumonia (HAP) can improve the outcom

40 Overall, hospital-acquired pneumonia (HAP) caused by Pseudomonas

41 Hospital-acquired pneumonia (HAP) due to gram-positive p

42 ening >=4 NIHSS points) before thrombectomy, hospital-acquired pneumonia (HAP) during hospitalization

43 otyped S. aureus isolates from patients with hospital-acquired pneumonia (HAP) enrolled in two regist

44 an audit on the adherence to guidelines for hospital-acquired pneumonia (HAP) for can improve the ou

45 ute respiratory distress syndrome (ARDS) and hospital-acquired pneumonia (HAP) in critically ill pati

46 Hospital-acquired pneumonia (HAP) is the most common and

47 Among 200 patients developing hospital-acquired pneumonia (HAP) outside the intensive

48 o characterize the systemic host response in hospital-acquired pneumonia (HAP) when compared with com

49 /tazobactam (P/T) in pediatric patients with hospital-acquired pneumonia (HAP).

50 8 (1.24-1.52); p < 0.0001) and even more ICU-hospital-acquired pneumonia (hazard ratio, 1.82 [1.35-2.

51 gh Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) database.

52 ed 150 patients (79.3% male) with sepsis and hospital-acquired pneumonia in 71.7% as the primary indi

53 emphasized the importance of preventing ICU-hospital-acquired pneumonia in nonventilated patients.

54 tion between acid-suppressive medication and hospital-acquired pneumonia in patients with acute strok

55 After adjustment, the OR of hospital-acquired pneumonia in the exposed group was 2.3

56 able logistic regression, the adjusted OR of hospital-acquired pneumonia in the group exposed to acid

57 t Pseudomonas aeruginosa, a leading cause of hospital-acquired pneumonia, interferes with the ability

58 Hospital-acquired pneumonia is a major cause of morbidit

59 p in all patients with community-acquired or hospital-acquired pneumonias is a crucial measure for ma

60 s (eg, individuals with ventilator-requiring hospital-acquired pneumonia), it is imperative to kill >

61 for ventilator-associated pneumonia and ICU-hospital-acquired pneumonia mortality due to P. aerugino

62 cally significant gastrointestinal bleeding, hospital-acquired pneumonia, mortality, and the use of e

63 ality rates for patients with non-ventilator hospital-acquired pneumonia (NV-HAP) are among the highe

64 Non-ventilator-associated hospital-acquired pneumonia (NV-HAP) is a common and dea

65 Ventilator-associated pneumonia and ICU-hospital-acquired pneumonia occurred in 1,161 at-risk pa

66 ication was ordered in 52% of admissions and hospital-acquired pneumonia occurred in 2219 admissions

67 ve medication was ordered in 1,340 (80%) and hospital-acquired pneumonia occurred in 289 (17.2%).

68 ceptor blockers did not increase the risk of hospital-acquired pneumonia (odds ratio 1.53; 95% confid

69 e included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pne

70 Lung bacterial infections, including hospital-acquired pneumonia, remain a serious problem fo

71 The incidence of hospital-acquired pneumonia remains high globally and tr

72 nsy, and significant decreases were seen for hospital-acquired pneumonia, scarlet fever, pyelonephrit

73 of P. aeruginosa isolates from patients with hospital-acquired pneumonia secreted type III proteins,

74 To determine the strategies of prevention of hospital-acquired pneumonia that reduce mortality in int

75 pulmonary infections and for the tendency of hospital-acquired pneumonia to be polymicrobial.

76 The unadjusted incidence of hospital-acquired pneumonia was higher in the group expo

77 The unadjusted incidence of hospital-acquired pneumonia was higher in the group expo

78 es of ventilator-associated pneumonia or ICU-hospital-acquired pneumonia were handled as time-depende